Status:
COMPLETED
Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure
Lead Sponsor:
An Sinh Hospital
Collaborating Sponsors:
Vietnam National University
Conditions:
Repeated Implantation Failure
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization an...
Detailed Description
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intraut...
Eligibility Criteria
Inclusion
- had repeated implantation failure
- have at least 1 good quality embryo for transfer
Exclusion
- uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01493440
Start Date
March 1 2011
End Date
September 1 2011
Last Update
December 20 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IVFAS, An Sinh Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam, 8